GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

US equity futures dropped as investors navigate the trade war and a busy slate of earnings from some of the world’s biggest ...